Q4 Revenue and Sequential Momentum
Q4 2025 revenue of $961M, reported sales increase of 6.2% and constant-currency growth of 2.5% (note: benefited from ~570 bps of onetime Byte refund/distributor pre-buys tailwind and +370 bps FX headwind/benefit mix). Management expects positive sequential sales momentum in H2 2026.
Adjusted EBITDA Margin Expansion for Full Year
Full year 2025 adjusted EBITDA margin expanded 150 bps to 18.1%, driven primarily by lower SG&A, demonstrating improved margin discipline despite gross profit pressure.
Profitability and Cash Generation
Q4 adjusted EPS of $0.27 (up $0.01, +4.9% year-over-year). Full year adjusted EPS $1.60 (in line with guidance). Q4 operating cash flow $101M and free cash flow $60M; full year operating cash flow $235M and free cash flow $104M. Ending cash of $326M and net debt/EBITDA of 3.0x.
Strong Performance in Several Product Areas and Regions
EDS constant-currency sales +4% in Q4 with preventative products up 17%; OIS reported constant-currency sales +6.9% (with Byte comparison effects); Wellspect constant-currency sales +1.9% with U.S. +15%; imaging posted high single-digit to double-digit growth in Europe/Rest of World for the year.
Return-to-Growth Plan and Investment Priorities
Management rolled out a 24-month 'Return to Growth' plan (5 pillars), plans to increase R&D spending by double digits, boost clinical education investment by 50%, reorganize commercial teams, and invest in scaling manufacturing/distribution. Plan targets ~ $120M annual run-rate savings to be reinvested.
Capital Allocation Shift
Company eliminated the dividend (~$128M annual), reallocating cash toward debt repayment and disciplined share repurchases to strengthen the balance sheet and support shareholder returns over time.